Margherita Passariello

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.

Journal: Journal of cardiovascular pharmacology

Published: October 06, 2025

Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy.

Generation of novel human anti-OX-40 mAbs endowed with different biological properties as tools for cancer therapy.

Journal: Frontiers in immunology

Published: June 10, 2025

A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.

A Novel Human Anti-FV mAb as a Potential Tool for Diagnostic and Coagulation Inhibitory Approaches.

Journal: International journal of molecular sciences

Published: January 20, 2025

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics.

Journal: Cell death discovery

Published: September 23, 2024

A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.

A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies.

Journal: Cancers

Published: October 02, 2023

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.

Journal: Frontiers in cardiovascular medicine

Published: May 31, 2023

Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.

Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.

Journal: iScience

Published: May 12, 2023

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays.

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays.

Journal: International journal of molecular sciences

Published: April 29, 2023

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways.

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways.

Journal: Frontiers in cardiovascular medicine

Published: December 22, 2022

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC.

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC.

Journal: Cancers

Published: September 22, 2022

Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.

Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 21, 2022

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.

Journal: International journal of molecular sciences

Published: May 02, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026